Suchergebnisse - (Person:"De Meyer, Sandra")

PubPharm (103)

81

Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240

enthalten in: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V | 2010

von Visser, M. | Baert, L. | Klooster, G. | +8

82

A quantitative evaluation of the molecular binding affinity between a monoclonal antibody conjugated to a nanoparticle and an antigen by surface plasmon resonance

enthalten in: European journal of pharmaceutics and biopharmaceutics | 2010

von Visser, M. | Baert, L. | Klooster, G. | +8

83

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients

enthalten in: Antiviral therapy | 2010

von Dierynck, I. | De Meyer, S. | Lathouwers, E. | +5

84

Research Letters - Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials

enthalten in: Aids | 2010

von Peeters, M. | Vingerhoets, J. | Tambuyzer, L. | +4

85

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

enthalten in: AIDS (London, England) | 2009

von De Meyer, S. | Lathouwers, E. | Dierynck, I. | +7

86

Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96

enthalten in: Antiviral therapy | 2009

von Arastéh, K. | Yeni, P. | Pozniak, A. | +7

87

Characterization of virologic failure patients on darunavir-ritonavir in treatment-experienced patients

enthalten in: Aids | 2009

von De Meyer, S. | Lathouwers, E. | Dierynck, I. | +7

88

Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2008

von De Meyer, S. | Hill, A. | Picchio, G. | +3

CommentOn: AIDS. 2007 Oct 18;21(16):2245-8. - PMID 18090054

89

Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2008

von De Meyer, S. | Spinosa-Guzman, S. | Vangeneugden, T. | +2

90

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

enthalten in: AIDS (London, England) | 2008

von Ortiz, R. | Dejesus, E. | Khanlou, H. | +9